Thus, adjuvant chemotherapy, which is associated with a 16% reduction in the risk of recurrence or death in NSCLC (HR for disease recurrence or death, 0.84),7 remains necessary for EGFR-mutated stage II-IIIA NSCLC when an EGFR-TKI was administered.26 Another possible reason for the OS benefit might be the sequential synergistic effect of chemotherapy and EGFR-TKIs. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.